• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞毒性T淋巴细胞相关抗原4的转运与表面表达

CTLA-4 trafficking and surface expression.

作者信息

Valk Elke, Rudd Christopher E, Schneider Helga

机构信息

Cell Signalling Section, Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK.

出版信息

Trends Immunol. 2008 Jun;29(6):272-9. doi: 10.1016/j.it.2008.02.011. Epub 2008 May 9.

DOI:10.1016/j.it.2008.02.011
PMID:18468488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4186961/
Abstract

The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4 is primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation. Recently, several signalling molecules such as Trim, PLD, ARF-1 and TIRC7 have been described to be involved in the transport of CTLA-4 to the cell surface. Minor changes in surface expression levels have major effects on the outcome of T-cell activation. Optimal regulation of CTLA-4 surface expression is crucial for the balance of stimulatory and inhibitory signals to maximize protective immune responses while maintaining immunological tolerance and preventing autoimmunity.

摘要

T细胞共受体细胞毒性T细胞抗原4(CTLA-4)具有很强的抑制作用,CTLA-4缺陷小鼠的淋巴细胞增殖表型就表明了这一点。尽管CTLA-4对T细胞功能有强大作用,但其主要是一种细胞内抗原,其表面表达通过限制转运至细胞表面和快速内化而受到严格调控。最近,已描述了几种信号分子,如TRIM、PLD、ARF-1和TIRC7参与CTLA-4向细胞表面的转运。表面表达水平的微小变化对T细胞活化的结果有重大影响。CTLA-4表面表达的最佳调节对于刺激和抑制信号的平衡至关重要,以在维持免疫耐受和预防自身免疫的同时最大化保护性免疫反应。

相似文献

1
CTLA-4 trafficking and surface expression.细胞毒性T淋巴细胞相关抗原4的转运与表面表达
Trends Immunol. 2008 Jun;29(6):272-9. doi: 10.1016/j.it.2008.02.011. Epub 2008 May 9.
2
CD28 and CTLA-4 coreceptor expression and signal transduction.CD28和CTLA-4共受体表达与信号转导。
Immunol Rev. 2009 May;229(1):12-26. doi: 10.1111/j.1600-065X.2009.00770.x.
3
T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.T细胞受体相互作用分子作为一种伴侣蛋白来调节共受体CTLA-4的表面表达。
Immunity. 2006 Nov;25(5):807-21. doi: 10.1016/j.immuni.2006.08.024. Epub 2006 Oct 26.
4
TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression.TIRC7 通过调节 CTLA-4 的表达来抑制 T 细胞增殖。
J Immunol. 2006 Nov 15;177(10):6833-41. doi: 10.4049/jimmunol.177.10.6833.
5
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.通过CTLA-4和PD-1途径控制外周T细胞耐受性和自身免疫
Immunol Rev. 2008 Aug;224:166-82. doi: 10.1111/j.1600-065X.2008.00662.x.
6
CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets.细胞毒性T淋巴细胞相关蛋白4共受体对调节性T细胞和CD8 + T细胞亚群的功能产生影响。
Eur J Immunol. 2009 Mar;39(3):687-90. doi: 10.1002/eji.200939261.
7
T-cell regulation by CD28 and CTLA-4.CD28和CTLA-4对T细胞的调节
Nat Rev Immunol. 2001 Dec;1(3):220-8. doi: 10.1038/35105024.
8
Human leukocyte antigen class I-restricted immunosuppression by human CD8+ regulatory T cells requires CTLA-4-mediated interaction with dendritic cells.人类CD8 +调节性T细胞介导的人类白细胞抗原I类限制性免疫抑制需要CTLA-4介导与树突状细胞的相互作用。
Hum Immunol. 2008 Nov;69(11):687-95. doi: 10.1016/j.humimm.2008.08.277. Epub 2008 Sep 24.
9
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity.CTLA-4 在调节性 T 细胞和常规 T 细胞中的双重功能,以预防多器官自身免疫。
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1524-8. doi: 10.1073/pnas.0910341107. Epub 2010 Jan 4.
10
Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation.抑制性免疫共受体 LAG-3 细胞质区的非典型基序抑制 T 细胞激活。
J Biol Chem. 2019 Apr 12;294(15):6017-6026. doi: 10.1074/jbc.RA119.007455. Epub 2019 Feb 13.

引用本文的文献

1
Negative Immune Checkpoint Inhibitors.阴性免疫检查点抑制剂
Pharmaceutics. 2025 May 28;17(6):713. doi: 10.3390/pharmaceutics17060713.
2
Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations.利用 GastroPlus 开发的英夫利昔单抗、伊匹木单抗和纳武单抗的基于生理的药代动力学模型,用于预测肝脏浓度。
Pharmaceutics. 2025 Mar 14;17(3):372. doi: 10.3390/pharmaceutics17030372.
3
Role of lysine-specific demethylase 1 in immunotherapy of gastric cancer: An update.

本文引用的文献

1
Differential inhibition of autoreactive memory- and alloreactive naive T cell responses by soluble cytotoxic T lymphocyte antigen 4 (sCTLA4), CTLA4Ig and LEA29Y.可溶性细胞毒性T淋巴细胞抗原4(sCTLA4)、CTLA4Ig和LEA29Y对自身反应性记忆T细胞和同种异体反应性幼稚T细胞反应的差异性抑制作用
Clin Exp Immunol. 2007 Dec;150(3):487-93. doi: 10.1111/j.1365-2249.2007.03513.x. Epub 2007 Oct 9.
2
Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells.CTLA-4的增强结合诱导抗原特异性CD4+CD25+Foxp3+和CD4+CD25-TGF-β1+适应性调节性T细胞。
J Immunol. 2007 Oct 15;179(8):5191-203. doi: 10.4049/jimmunol.179.8.5191.
3
赖氨酸特异性去甲基化酶1在胃癌免疫治疗中的作用:最新进展
Chin J Cancer Res. 2024 Dec 30;36(6):669-682. doi: 10.21147/j.issn.1000-9604.2024.06.06.
4
Identification of a novel molecular classification for hepatocellular carcinoma based on disulfideptosis-related genes and its potential prognostic significance.基于二硫键细胞凋亡相关基因的新型肝癌分子分类及其潜在预后意义。
J Cancer Res Clin Oncol. 2024 Nov 18;150(12):506. doi: 10.1007/s00432-024-06031-7.
5
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.博滕西利单抗,一种Fc增强型抗CTLA-4抗体,对传统免疫疗法反应不佳的肿瘤有效。
Cancer Discov. 2024 Dec 2;14(12):2407-2429. doi: 10.1158/2159-8290.CD-24-0190.
6
Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.结直肠癌治疗的当前与未来趋势:探索免疫疗法的进展
Cancers (Basel). 2024 May 24;16(11):1995. doi: 10.3390/cancers16111995.
7
CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer.C反应蛋白和可溶性细胞毒性T淋巴细胞相关抗原4是胃肠道癌抗程序性死亡蛋白1治疗耐药性的决定因素。
Am J Cancer Res. 2024 Mar 15;14(3):1174-1189. doi: 10.62347/NQBL9998. eCollection 2024.
8
Molecular Subtypes, microRNAs and Immunotherapy Response in Metastatic Colorectal Cancer.转移性结直肠癌的分子亚型、microRNAs 和免疫治疗反应。
Medicina (Kaunas). 2024 Feb 26;60(3):397. doi: 10.3390/medicina60030397.
9
Modern cancer therapy: cryoablation meets immune checkpoint blockade.现代癌症治疗:冷冻消融与免疫检查点阻断相结合。
Front Oncol. 2024 Feb 7;14:1323070. doi: 10.3389/fonc.2024.1323070. eCollection 2024.
10
Five Inhibitory Receptors Display Distinct Vesicular Distributions in Murine T Cells.五种抑制性受体在小鼠 T 细胞中呈现不同的囊泡分布。
Cells. 2023 Oct 31;12(21):2558. doi: 10.3390/cells12212558.
Induction of the CTLA-4 gene in human lymphocytes is dependent on NFAT binding the proximal promoter.
人淋巴细胞中CTLA-4基因的诱导依赖于NFAT与近端启动子的结合。
J Immunol. 2007 Sep 15;179(6):3831-40. doi: 10.4049/jimmunol.179.6.3831.
4
TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression.TIRC7 通过调节 CTLA-4 的表达来抑制 T 细胞增殖。
J Immunol. 2006 Nov 15;177(10):6833-41. doi: 10.4049/jimmunol.177.10.6833.
5
T cell receptor-interacting molecule acts as a chaperone to modulate surface expression of the CTLA-4 coreceptor.T细胞受体相互作用分子作为一种伴侣蛋白来调节共受体CTLA-4的表面表达。
Immunity. 2006 Nov;25(5):807-21. doi: 10.1016/j.immuni.2006.08.024. Epub 2006 Oct 26.
6
Retrograde transport from endosomes to the trans-Golgi network.从内体到反式高尔基体网络的逆行运输。
Nat Rev Mol Cell Biol. 2006 Aug;7(8):568-79. doi: 10.1038/nrm1985.
7
Reversal of the TCR stop signal by CTLA-4.细胞毒性T淋巴细胞相关抗原4(CTLA-4)对T细胞受体(TCR)终止信号的逆转作用
Science. 2006 Sep 29;313(5795):1972-5. doi: 10.1126/science.1131078. Epub 2006 Aug 24.
8
ARF proteins: roles in membrane traffic and beyond.ARF蛋白:在膜泡运输及其他方面的作用
Nat Rev Mol Cell Biol. 2006 May;7(5):347-58. doi: 10.1038/nrm1910.
9
Normal T-cell development and immune functions in TRIM-deficient mice.TRIM 缺陷小鼠的正常 T 细胞发育和免疫功能
Mol Cell Biol. 2006 May;26(9):3639-48. doi: 10.1128/MCB.26.9.3639-3648.2006.
10
A molecular perspective of CTLA-4 function.CTLA-4功能的分子视角。
Annu Rev Immunol. 2006;24:65-97. doi: 10.1146/annurev.immunol.24.021605.090535.